B7-h4 expression on tumor vasculature

Abstract

Methods of evaluating patients by assessing expression of B7-H4 in the vasculature are described.

1 - 25 . (canceled) 
     
     
         26 . A method of treating a cancer patient, said method comprising:
 (a) identifying a patient as having a tumor that is B7-H4 negative but that exhibits B7-H4 expression in the tumor vasculature; and   (b) delivering to said patient an agent that reduces B7-H4 activity.   
     
     
         27 . The method of  claim 26 , wherein said agent comprises an antibody or a fragment thereof. 
     
     
         28 . The method of  claim 27 , wherein said antibody fragment is selected from the group consisting of an Fab′ fragment, an F(ab′)2 fragment, or a single chain Fv fragment. 
     
     
         29 . The method of  claim 26 , wherein said agent binds to B7-H4. 
     
     
         30 . The method of  claim 26 , wherein said B7-H4 activity is decreased CD4+ and CD8+ T cell proliferation. 
     
     
         31 . The method of  claim 26 , further comprising delivering to said patient one or more immunomodulatory cytokines, growth factors, or anti-angiogenic factors. 
     
     
         32 . The method of  claim 31 , wherein said one or more immunomodulatory cytokines, growth factors, or anti-angiogenic factors are selected from the group consisting of interleukin (IL)-1 to IL-25, interferon-alpha (IFN-α), interferon-beta (IFN-(β), interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), granulocyte macrophage colony stimulating factor (GM-CSF), endostatin, angiostatin, and thrombospondin. 
     
     
         33 . The method of  claim 26 , wherein said patient has a cancer selected from the group consisting of hematological cancer, neurological cancer, melanoma, breast cancer, lung cancer, head and neck cancer, gastrointestinal cancer, liver cancer, pancreatic cancer, renal cancer, genitourinary cancer, bone cancer, and vascular cancer. 
     
     
         34 . The method of  claim 33 , wherein said cancer is a renal cell carcinoma. 
     
     
         35 . The method of  claim 26 , wherein said agent is an antisense oligonucleotide that hybridizes to a B7-H4 transcript. 
     
     
         36 . The method of  claim 26 , wherein said agent is an interference RNA (RNAi). 
     
     
         37 . A method of increasing CD4+ and CD8+ T cell proliferation in a cancer patient, said method comprising:
 (a) identifying a patient as having a tumor that is B7-H4 negative but that exhibits B7-H4 expression in the tumor vasculature; and   (b) delivering to said patient an agent that reduces B7-H4 activity.   
     
     
         38 . The method of  claim 37 , wherein said agent comprises an antibody or a fragment thereof. 
     
     
         39 . The method of  claim 38 , wherein said antibody fragment is selected from the group consisting of an Fab′ fragment, an F(ab′)2 fragment, or a single chain Fv fragment. 
     
     
         40 . The method of  claim 37 , wherein said agent binds to B7-H4. 
     
     
         41 . The method of  claim 37 , further comprising delivering to said patient one or more immunomodulatory cytokines, growth factors, or anti-angiogenic factors. 
     
     
         42 . The method of  claim 41 , wherein said one or more immunomodulatory cytokines, growth factors, or anti-angiogenic factors are selected from the group consisting of IL-1 to IL-25, IFN-α, IFN-β, IFN-γ, TNF-α, GM-CSF, endostatin, angiostatin, and thrombospondin. 
     
     
         43 . The method of  claim 37 , wherein said patient has a cancer selected from the group consisting of hematological cancer, neurological cancer, melanoma, breast cancer, lung cancer, head and neck cancer, gastrointestinal cancer, liver cancer, pancreatic cancer, renal cancer, genitourinary cancer, bone cancer, and vascular cancer. 
     
     
         44 . The method of  claim 43 , wherein said cancer is a renal cell carcinoma. 
     
     
         45 . The method of  claim 37 , wherein said agent is an antisense oligonucleotide that hybridizes to a B7-H4 transcript. 
     
     
         46 . The method of  claim 37 , wherein said agent is an RNAi.